22 New and approved therapies for SLE: Anifrolumab | Lupus Science & Medicine

Log In More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest content

Archive

Authors

About

Podcasts
Log in More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals

Citation Tools

Abstracts

Prime time session: treatment targets and novel therapies

22 New and approved therapies for SLE: Anifrolumab

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:: Vollenhoven RV

22 New and approved therapies for SLE: Anifrolumab

Lupus Science & Medicine 2022;9:doi: 10.1136/lupus-2022-la.22